Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

abstract：:Acute megakaryocytic leukemia (AMKL) was defined as a new subtype of acute nonlymphocytic leukemia (ANLL) by the French-American-British (FAB) Cooperative Group in 1985. The first consistent chromosomal anomaly described in this subset of ANLL was the translocation t(1;22)(p13;q13) which appears to be restricted to th...

journal_title：Leukemia & lymphoma

authors： Lion T,Haas OA

更新日期：1993-09-01 00:00:00

abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

journal_title：Leukemia & lymphoma

authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

更新日期：2016-07-01 00:00:00

abstract：:We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

journal_title：Leukemia & lymphoma

authors： McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

更新日期：1998-06-01 00:00:00

abstract：:A kindred with familial leukemia is described in which three members are affected by leukemia in three consecutive generations. One of these members had Philadelphia positive chronic myeloid leukemia (CML) and other two had precursor B acute lymphoblasticleukemia (ALL)--Philadelphia negative. All three of them shared ...

journal_title：Leukemia & lymphoma

authors： Kuruvilla J,Gupta V,Gill KS,Lipton JH

更新日期：2003-02-01 00:00:00

abstract：:The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

journal_title：Leukemia & lymphoma

authors： Chattopadhyay A,Abecassis I,Redner RL

更新日期：2015-01-01 00:00:00

abstract：:The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...

journal_title：Leukemia & lymphoma

authors： Muroi K,Nakamura M,Amemiya Y,Suda T,Miura Y

更新日期：1995-01-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

journal_title：Leukemia & lymphoma

authors： Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

更新日期：2004-08-01 00:00:00

abstract：:The role of malnutrition at diagnosis as a predictor of early mortality in Mexican leukemia children remains controversial. The objective of present study was to investigate whether malnutrition was a predictor of early mortality during the first year of treatment in Mexican acute lymphoblastic leukemia (ALL) children...

journal_title：Leukemia & lymphoma

authors： Martín-Trejo JA,Núñez-Enríquez JC,Fajardo-Gutiérrez A,Medina-Sansón A,Flores-Lujano J,Jiménez-Hernández E,Amador-Sanchez R,Peñaloza-Gonzalez JG,Alvarez-Rodriguez FJ,Bolea-Murga V,Espinosa-Elizondo RM,de Diego Flores-Chapa J,Pérez

更新日期：2017-04-01 00:00:00

abstract：:We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in...

journal_title：Leukemia & lymphoma

authors： Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F

更新日期：2019-04-01 00:00:00

abstract：:The role of cyclic AMP (cAMP) as second messenger in erythropoiesis has been suggested in the early 1980s. However, careful analysis showed that cAMP is not generated in direct response to the main erythropoiesis-controlling cytokines such as erythropoietin (Epo). As a result, cAMP disappeared from the central stage i...

journal_title：Leukemia & lymphoma

authors： Boer AK,Drayer AL,Vellenga E

更新日期：2003-11-01 00:00:00

abstract：:A patient with primary biliary cirrhosis (PBC) who developed idiopathic myelofibrosis (IM) is reported. The initial diagnosis of PBC was established by liver biopsy, performed after a 2-month history of constitutional symptoms associated with abnormalities of the serum liver enzymes, with typical serum immunological m...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Jiménez M,Rosiñol L,Cervantes F

更新日期：2002-03-01 00:00:00

abstract：:In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

journal_title：Leukemia & lymphoma

authors： Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

更新日期：2020-08-01 00:00:00

abstract：:In order to clarify the relationship between myelodysplastic morphologic features of marrow cells and prognoses and 1.0 define other prognostic factors, 124 patients with the FAB criteria of myelodysplastic syndrome (MIX) were analysed. These included 57 patients with refractory anemia (RA), 5 RA with ring sideroblast...

journal_title：Leukemia & lymphoma

authors： Takahashi M,Koike T,Kishi K,Moriyama Y,Hayashi S,Shibata A

更新日期：1990-01-01 00:00:00

abstract：:Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

journal_title：Leukemia & lymphoma

authors： Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

更新日期：2010-02-01 00:00:00

abstract：:We have analyzed the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples. In all patients, bcr-abl and HoxA9 were expressed at detectable levels in every sample. When t...

journal_title：Leukemia & lymphoma

authors： Tedeschi FA,Cardozo MA,Valentini R,Zalazar FE

更新日期：2010-05-01 00:00:00

abstract：:Tsg101 is a mouse tumor suppressor gene whose homozygous deletion produces transformation of NIH3T3 cells and leads to metastases in nude mice. The human homologue of the gene, TSG101, is localized in chromosome 11p15.1-p15.2. Reduced TSG101 expression may cause the defect of the cell cycle checkpoint that leads to ge...

journal_title：Leukemia & lymphoma

authors： Lin SF,Lin PM,Liu TC,Chang JG,Sue YC,Chen TP

更新日期：2000-02-01 00:00:00

abstract：:Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

journal_title：Leukemia & lymphoma

authors： Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

更新日期：1999-03-01 00:00:00

abstract：:There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

journal_title：Leukemia & lymphoma

authors： Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

更新日期：2019-08-01 00:00:00

abstract：:Gaucher disease (GD) is the most frequent lysosomal storage disease and corresponds to an inherited deficiency of glucocerebrosidase. Due to excessive accumulation of glucocerebroside in bone marrow, both cytopenia and bone lesions may occur. The incidence of malignant disorders has been evoked in non-neuronopathic ty...

journal_title：Leukemia & lymphoma

authors： Costello R,O'Callaghan T,Sébahoun G

更新日期：2006-07-01 00:00:00

abstract：:Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

journal_title：Leukemia & lymphoma

authors： Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

更新日期：2012-05-01 00:00:00

abstract：:Recombinant interleukin-21 (IL-21) has potential utility in cancer therapy. Stimulation with IL-21 can induce apoptosis in follicular lymphoma (FL) cells, and existing studies have suggested that IL-21 signaling may function in tumor suppression. In order to elucidate the relationship between IL-21 receptor (IL-21R) e...

journal_title：Leukemia & lymphoma

authors： Wood B,Sikdar S,Choi SJ,Virk S,Alhejaily A,Baetz T,LeBrun DP

更新日期：2013-06-01 00:00:00

abstract：:We studied the outcome of 213 patients who received allo-HSCT for hematological malignancies, 121 (57%) from HLA identical siblings, 63 (29%) from 10/10 HLA identical unrelated donors and 29 (14%) from 9/10 HLA mismatched unrelated donors. Engraftment was lower in the 9/10 HLA group (90%) than in the 10/10 HLA group (...

journal_title：Leukemia & lymphoma

authors： Michallet M,Sobh M,Serrier C,Morisset S,Labussière H,Ducastelle S,Barraco F,Gilis L,Thomas X,Nicolini FE

更新日期：2015-04-01 00:00:00

abstract：:In a woman with chronic lymphocytic leukemia (CLL), a plasmacytoma developed on the back region after four years. CLL cases complicated with plasmacytoma are rare. In the present case, the plasmacytoma showed kappa cytoplasmic immunoglobulin (Ig), and the CLL showed gamma lambda surface Ig. To reveal the clonal origin...

journal_title：Leukemia & lymphoma

authors： Yahata N,Iwase O,Iwama H,Tauchi T,Kawanishi Y,Serizawa H,Ohyashiki K

更新日期：2000-09-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:We examined dietary patterns and the risk of non-Hodgkin lymphoma (NHL) in the Multiethnic Cohort, which includes more than 215,000 Caucasians, African-Americans, Japanese-Americans, Native Hawaiians, and Latinos aged 45-75 at baseline. All subjects completed a validated food-frequency questionnaire. After a median fo...

journal_title：Leukemia & lymphoma

authors： Erber E,Maskarinec G,Gill JK,Park SY,Kolonel LN

更新日期：2009-08-01 00:00:00

abstract：:The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era. We assessed Ki67 and PIM1 (a cell cycle-related gene upregulated in blastoid MCL) expression by immunohistochemistry in a phase II study Cancer and Leukemia Group B 59909 of ...

journal_title：Leukemia & lymphoma

authors： Hsi ED,Jung SH,Lai R,Johnson JL,Cook JR,Jones D,Devos S,Cheson BD,Damon LE,Said J

更新日期：2008-11-01 00:00:00

abstract：:Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

journal_title：Leukemia & lymphoma

authors： Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

更新日期：2011-06-01 00:00:00

abstract：:One possible reason for the relapse and refractoriness of extranodal natural killer/T-cell (NK/T) lymphoma (ENKL) is resistance to a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). To evaluate the outcome of first-line EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophospha...

journal_title：Leukemia & lymphoma

authors： Huang H,Lin Z,Lin X,Cai Q,Xia Z,Jiang W

更新日期：2011-06-01 00:00:00

abstract：:The MRC has conducted randomised trials in CLL sine 1978: CLL 1 (1978-84), 660 patients; CLL 2 (1984-90), 640 patients; CLL 3 (from June 1990), 90 patients. Centralised morphological diagnosis and membrane marker studies have allowed the exclusion of non-CLL disorders. Some of the treatment questions were repeated in ...

journal_title：Leukemia & lymphoma

authors： Catovsky D,Richards S,Fooks J,Hamblin TJ

更新日期：1991-01-01 00:00:00

abstract：:B cell non-Hodgkin lymphomas (B-NHLs) are the most common adult hematological cancers and many remain incurable. Development of chemotherapy regimens is confounded by the prevalence of B-NHL in older, frailer patients and the chemo-protective tumor microenvironment. Although biological therapies such as rituximab have...

journal_title：Leukemia & lymphoma

authors： Hayden RE,Kussaibati R,Cronin LM,Pratt G,Roberts C,Drayson MT,Bunce CM

更新日期：2015-04-01 00:00:00